The intrepid young oncologist's criticism of cancer screening and surrogate endpoints has stirred up controversy. He says he just wants drugmakers, others to meet high standards of evidence.
|Original language||English (US)|
|Specialist publication||Managed Care|
|State||Published - 2016|
ASJC Scopus subject areas
- Health Policy
- Public Health, Environmental and Occupational Health